Afrezza, an innovative inhalable insulin formulation, offers a rapid-acting alternative for managing postprandial hyperglycemia in people with type 1 and type 2 diabetes. Unlike traditional injectable insulins, Afrezza utilizes a dry-powder delivery system that is inhaled through the lungs, providing a needle-free option that can improve adherence and quality of life. However, bringing such a novel drug delivery system to patients requires navigating complex, country-specific regulatory pathways. Each nation’s regulatory agency imposes distinct requirements to verify the safety, efficacy, and manufacturing quality of this unique product.

This article provides a comprehensive, authoritative walkthrough of the regulatory approval process for Afrezza across major global markets, including the United States, the European Union, Japan, Canada, Australia, and emerging economies. We examine the specific steps, timelines, clinical trial expectations, and post-marketing surveillance protocols that shape Afrezza’s availability worldwide. Understanding these divergent frameworks is essential for healthcare professionals, diabetes patients, and industry stakeholders who seek to comprehend how regulatory science balances innovation with patient protection.

The Core Pillars of Drug Regulation

Although each country has its own drug approval system, nearly all regulatory frameworks rest on three foundational pillars: quality (manufacturing consistency and purity), safety (acceptable risk profile based on preclinical and clinical data), and efficacy (demonstrated benefit in well-designed clinical trials). For Afrezza, an inhaled insulin, the safety pillar is particularly scrutinized because the drug must demonstrate that it does not cause unacceptable pulmonary toxicity, such as lung function decline, inflammation, or long-term fibrosis. Regulatory agencies also require robust evidence that the inhaler device delivers a reproducible and accurate dose under everyday conditions.

The approval journey begins with a New Drug Application (NDA) or Marketing Authorization Application (MAA) submission. The manufacturer compiles a dossier containing data from phase 1, 2, and 3 clinical trials, pharmacokinetic and pharmacodynamic studies, stability testing, and manufacturing process validation. The regulatory agency then conducts a thorough review, often involving advisory committee meetings, site inspections, and labeling negotiations. Once approved, the agency imposes post-market requirements, such as risk evaluation and mitigation strategies (REMS) or additional long-term safety studies.

United States: The FDA Pathway

The U.S. Food and Drug Administration (FDA) approved Afrezza in June 2014 for the treatment of adults with diabetes mellitus. The approval followed a rigorous review of an NDA submitted by MannKind Corporation. The FDA’s decision was not without controversy; two advisory committee votes in 2010 and 2011 initially recommended against approval due to concerns about pulmonary safety and the absence of a clear efficacy advantage over existing rapid-acting insulins. However, after additional clinical trials and revised analyses, the FDA granted approval with a boxed warning regarding the risk of acute bronchospasm in patients with chronic lung diseases such as asthma and COPD.

Clinical Data Requirements

The FDA required MannKind to submit data from the Affinity 1 and Affinity 2 phase 3 trials, which enrolled over 2,500 patients. These studies compared Afrezza to placebo and to subcutaneous insulin aspart in terms of HbA1c reduction and hypoglycemia rates. Critically, the FDA mandated dedicated pulmonary function tests (spirometry, diffusing capacity) to rule out significant lung impairment. The approved labeling includes a contraindication for patients with asthma or COPD, and a warning about the need for annual spirometry monitoring.

Manufacturing and Device Review

The FDA also scrutinized the inhaler device, known as the Dreamboat or later the Humulin inhaler. The agency required evidence of dose consistency at different flow rates and humidity conditions, as well as human factors testing to ensure patients could correctly load and inhale the cartridge. The manufacturer had to submit a detailed description of the cartridge filling process and particulate characterization.

Post-Approval Requirements

Following approval, the FDA mandated a Risk Evaluation and Mitigation Strategy (REMS) to ensure that prescribers educate patients about safe use, proper inhalation technique, and the importance of avoiding use in patients with chronic lung disease. Additionally, the FDA required a long-term observational study (the INHALE study) to monitor pulmonary safety in real-world use over five years. Results from the INHALE study, reported in 2022, showed no significant decline in lung function attributable to Afrezza, although caution remains for susceptible individuals.

European Union: The Centralized EMA Process

In the European Union, Afrezza is not currently approved for marketing. The manufacturer submitted a Marketing Authorization Application to the European Medicines Agency (EMA) in 2013, but the Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion in early 2014. The EMA’s primary concerns mirrored the FDA’s early reservations: insufficient evidence of clinically meaningful benefit over existing formulations and unresolved questions about long-term pulmonary safety. The company subsequently withdrew the application.

Regulatory Hurdles in Europe

The EU’s centralized procedure requires the manufacturer to demonstrate that the new drug offers a significant therapeutic advantage over available treatments. For Afrezza, the CHMP noted that the reduction in HbA1c was comparable to that of insulin aspart, but the convenience of inhaled delivery was not deemed sufficient to outweigh the potential risks. The EMA also wanted longer-term data on lung function from a larger patient population, particularly in patients with mild asthma. Without an approved EU pathway, Afrezza is not available in EU member states except through named-patient programs or compassionate use in rare cases.

Parallel National Procedures

Companies may also seek approval through decentralized or mutual recognition procedures if a drug is already approved in one EU member state. However, because Afrezza has not been approved in any EU country, those pathways are not feasible. To re-enter the EU market, the manufacturer would likely need to conduct new clinical trials specifically addressing the CHMP’s concerns, perhaps focusing on a patient population with greater unmet need, such as those with severe injection phobia or needle aversion.

Japan: The PMDA’s Stringent Standards

Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has not approved Afrezza for marketing. Inhaled insulin faces especially high hurdles in Japan because of the country’s strict requirements for local clinical data and its unique demographic characteristics, including a high prevalence of asthma and smoking-related lung diseases. The PMDA typically requires a bridging study or a full ethnic-differentiation study to confirm that pharmacokinetics and safety profiles are comparable between Japanese and Caucasian populations.

Bridging Studies and Ethnic Factors

Even if the manufacturer were to submit trial data from the U.S. or global studies, the PMDA would likely request a randomized, controlled trial in Japanese patients with type 2 diabetes to assess HbA1c efficacy and, critically, pulmonary function changes. Given the small market potential for an inhaled insulin in Japan, combined with the high cost of conducting such a trial, Afrezza’s approval in Japan remains improbable unless a local partner invests significantly in the development program.

Canada: Health Canada’s Modulated Approach

Health Canada approved Afrezza in 2014, following the FDA’s lead but with additional conditions. The approval was granted under the Notice of Compliance with Conditions (NOC/c) policy, which allows early access to promising drugs for serious conditions pending further confirmatory trials. Health Canada required the manufacturer to conduct a post-market study to confirm the long-term pulmonary safety and to report on real-world hypoglycemia rates.

Canadian Risk Management

Health Canada imposed a comprehensive risk-management plan (RMP) that includes mandatory prescriber training, patient educational materials, and a registry for monitoring adverse events. The Canadian labeling includes a contraindication for smoking (due to altered absorption) and for patients with asthma or COPD. Interestingly, Health Canada also required an aerodynamic particle-size distribution analysis to ensure that the fine-particle fraction of the emitted dose remained consistent under Canadian climatic conditions (e.g., cold, dry winters).

Despite the conditional approval, Afrezza’s commercial launch in Canada was delayed and has had limited uptake, partly due to pricing negotiations and the requirement for annual spirometry monitoring, which adds cost and complexity for physicians and patients.

Australia: TGA and the ARTG

The Australian Therapeutic Goods Administration (TGA) approved Afrezza in 2016, after reviewing the same core clinical data submitted to the FDA and Health Canada. The TGA’s approval was not subject to an NOC/c; instead, it was a standard registration on the Australian Register of Therapeutic Goods (ARTG). However, the TGA required a comprehensive product information document that includes strong warnings about the risks of bronchitis and cough, as well as a recommendation for baseline and yearly spirometry.

Reimbursement Challenges

In Australia, approval and reimbursement are separate processes. Afrezza is not listed on the Pharmaceutical Benefits Scheme (PBS), which means patients must pay the full price out-of-pocket. This lack of reimbursement has severely limited adoption. To get PBS listing, the manufacturer would need to demonstrate cost-effectiveness through a formal submission to the Pharmaceutical Benefits Advisory Committee (PBAC), which would likely require further head-to-head studies with insulin analogues and evidence of reduced injection-related complications.

Emerging Markets: India, Brazil, and Others

Regulatory pathways in emerging markets vary widely. In India, the Central Drugs Standard Control Organization (CDSCO) has not approved Afrezza. The Indian regulatory environment requires a local clinical trial if the drug is intended for a disease with high prevalence in the Indian population, and the affordable pricing of generic injectable insulins makes the economic case for Afrezza weak. However, a few patients have imported Afrezza through special license approval.

In Brazil, the Agência Nacional de Vigilância Sanitária (ANVISA) has not approved Afrezza. The approval process in Brazil is notoriously lengthy, and the agency often requires extensive local data on bioequivalence and safety. Given the high burden of diabetes in Brazil, there is some interest, but the manufacturer has not submitted a complete application as of 2024.

In the Middle East, countries like Saudi Arabia and the United Arab Emirates have their own regulatory bodies that often accept decisions from the FDA or EMA as reference agencies. Afrezza is registered in a few Gulf Cooperation Council (GCC) states, but market access is limited by pricing and the need for specialized training for healthcare providers.

Harmonization Efforts and Their Impact on Afrezza

International regulatory harmonization initiatives, such as the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), aim to reduce duplication and streamline global drug development. For a product like Afrezza, harmonization could mean that a single pivotal clinical trial conducted in the U.S. might satisfy requirements in multiple countries, provided that the patient population is diverse enough and that regional sensitivities (e.g., pulmonary baseline health) are addressed. The Project Orbis initiative, run by the FDA in collaboration with agencies in Canada, Australia, and other countries, allows simultaneous review of oncology drugs. Although not applicable to diabetes therapies yet, similar initiatives for non-oncology drugs could accelerate Afrezza’s global approvals.

Nevertheless, differences in local clinical practice, healthcare infrastructure, and disease epidemiology continue to create friction. For instance, the FDA accepts surrogate endpoints like HbA1c as primary efficacy measures, while the EMA may require outcomes like reduced hypoglycemia or improved patient-reported outcomes to demonstrate added value. These differences force manufacturers to design multi-arm trials that satisfy multiple agencies simultaneously, increasing development costs and time.

Clinical Trial Design Considerations Across Regions

The design of clinical trials for inhaled insulin must accommodate the specific preferences of each regulatory agency. In the U.S., the FDA generally requires active-comparator trials for fast-acting insulins to show non-inferiority in HbA1c reduction, along with clear data on hypoglycemia rates. In Europe, the EMA prefers superiority trials that demonstrate a clinically meaningful advantage. For Afrezza, non-inferiority was not enough for the CHMP. Future approval efforts in Europe will likely require a superiority design focusing on patient-reported outcomes like satisfaction, quality of life, or reduction in severe hypoglycemia in a specific subgroup, such as type 1 diabetes patients with hypoglycemia unawareness.

Pulmonary safety endpoints also diverge. The FDA accepts a less than 5% decline in FEV1 over 12 months as clinically non-significant, whereas other agencies may require a narrower confidence interval. The PMDA in Japan might demand longer follow-up (at least 24 months) in a Japanese population. These differences mean that a single global development program may need to include both non-inferiority and superiority analyses, as well as separate pulmonary safety cohorts for different regions.

Real-World Data and Post-Approval Evidence

Real-world evidence (RWE) is becoming increasingly important for regulatory decisions. Pharmacovigilance databases and electronic health records can provide safety signals that complement controlled trials. For Afrezza, post-approval studies like the U.S. INHALE study have provided reassurance. However, in regions where the product never gained approval, RWE from other countries can sometimes be used to support a future application, if the patient demographics and usage patterns are similar.

Challenges and Barriers to Global Access

Several persistent challenges hinder broader global access to Afrezza:

  • Pulmonary safety concerns remain the leading barrier. Even though long-term data have not shown significant lung injury, the boxed warning in the U.S. and the total rejection in Europe reflect a precautionary principle that differs by region.
  • Cost and pricing – Afrezza is more expensive than injectable insulins. Without reimbursement approval, it remains a niche product for affluent patients.
  • Device complexity – The inhaler requires proper technique, and moisture can degrade the powder. This limits usability in humid climates.
  • Clinical inertia – Many physicians are comfortable with injectable insulins and see no urgent need to switch. The lack of clear superiority in hard outcomes makes the case for change less compelling.
  • Regulatory fragmentation – Each country imposes unique data requirements, leading to duplicated trials and high development costs.

The Future of Inhaled Insulin Regulation

The regulatory landscape for inhaled insulin is slowly evolving. As more real-world safety data accumulate, some agencies may relax their requirements. The FDA has already updated its guidance for pulmonary drug-device combinations, acknowledging that device design and patient training can mitigate aerosol deposition variability. Newer inhaled insulin products, such as Exubera (withdrawn) and others in development, may benefit from the regulatory precedent set by Afrezza. Additionally, regulatory agencies are increasingly accepting patient preference data as part of the benefit-risk assessment. If studies show that patients strongly prefer inhaled insulin despite a slightly higher risk of cough or mild decline in lung function, regulators may weigh that preference more heavily in future decisions.

For diabetes, the ultimate goal is to provide a spectrum of treatment options that meet diverse patient needs. Regulatory processes that balance innovation with caution are essential. Understanding the nuances of Afrezza’s approval journey in different countries sheds light on the broader dynamics of global drug regulation.

External resources for further reading:

Conclusion

The regulatory approval process for Afrezza exemplifies the challenges inherent in bringing a novel drug-device combination to a global market. While the U.S. FDA and Health Canada granted approvals with strict monitoring conditions, the EMA and PMDA declined the product, citing insufficient evidence of added value and unresolved pulmonary safety concerns. These divergent decisions reflect not only differences in scientific interpretation but also in societal tolerance for risk and the value placed on convenience versus established treatments. For patients, the result is a fragmented landscape where access to Afrezza depends on geography, insurance, and sometimes direct importation. As diabetes care continues to evolve, ongoing communication between regulators, manufacturers, clinicians, and patients will be essential to refine the approval pathways for inhaled insulins and other novel therapies. The ultimate aim remains the same across all jurisdictions: to ensure that any medication reaching patients is both safe and effective, while broadening the array of tools available to manage this chronic disease effectively.